Convergent Synthesis and Discovery of a Natural Product-Inspired Paralog-Selective Hsp90 Inhibitor

Organic Letters

Volumn 13, Issue 19, 2011, Pages 5108-5111

  Jeso, Valer ^a   Cherry, Lisa ^b   Macklin, Todd K ^a   Pan, Subhas Chandra ^a   LoGrasso, Philip V ^a   Micalizio, Glenn C ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Translational Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOQUINONE; BENZOQUINONE DERIVATIVE; BIOLOGICAL PRODUCT; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

BENZOQUINONES; BIOLOGICAL AGENTS; HSP90 HEAT-SHOCK PROTEINS; LACTAMS, MACROCYCLIC; MOLECULAR STRUCTURE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80054747219     PISSN: 15237060     EISSN: 15237052     Source Type: Journal    
DOI: 10.1021/ol2019828     Document Type: Article

References (31)

1. For recent reviews on the biological activity of benzoquinone ansamycins, see: (a) Xu, W.; Neckers, L. Clin. Cancer Res. 2007, 13, 1625-1629.
2. Miyata, Y. Curr. Pharm. Des. 2005, 11, 1131-1138.
3. Baker, R.; Castro, J. L. J. Chem. Soc., Chem. Commun. 1989, 378-381.
4. Baker, R.; Castro, J. L. J. Chem. Soc., Perkin Trans. 1 1990, 47-65.
5. Whitesell, L.; Mimnaugh, E. G.; De Costa, B.; Myers, C. E.; Neckers, L. M. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 8324-8328.
6. Neckers, L. Trends Mol. Med. 2002, 8, S55-S61.
7. Chandarlapaty, S.; Sawai, A.; Ye, Q.; Scott, A.; Silinski, M.; Huang, K.; Fadden, P.; Partridge, J.; Hall, S.; Steed, P.; Norton, L.; Rosen, N.; Solit, D. B. Clin. Cancer Res. 2008, 14, 240-248.
8. Ferrarini, M.; Heltai, S.; Zocchi,M. R.; Rugarli, C. Int. J. Cancer 1992, 51, 613-619.
9. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. Nature 2003, 425, 407-410.
10. Snader, K.M.; Neckers, L.M.;Wishnuvajjala, B. R.; Sausville, E.A.;Xu,W.;Rosser,M.R.;Nicchitta,C.; Isaacs, J.A. (TheGovernment of the United States of America; National Institutes ofHealth). Geldanamycin derivatives useful for the treatment of cancer. WO application 200236574, May 10, 2002.
11. For structures of natural products bound to Hsp90 and GRP94, see: (b) Immormino, R. M.; Metzger, L. E. IV; Reardon, P. N.; Dollins, D. E.; Blagg, B. S. J.; Gewirth, D. T. J. Mol. Biol. 2009, 388, 1033-1042.
12. Wrona, I. E.; Gozman, A.; Taldone, T.; Chiosis, G.; Panek, J. S. J. Org. Chem. 2010, 75, 2820-2835.
13. Belardi, J. K.; Micalizio, G. C. Angew. Chem., Int. Ed. 2008, 47, 4005-4008.
14. Belardi, J. K.; Micalizio, G. C. Org. Lett. 2006, 8, 2409-2412.
15. For an early example of using engineered biosynthesis for the preparation of geldnamaycin analogs lacking a central quinone, see: Patel, K.; Piagentini, M.; Rascher, A.; Tian, Z.-Q.; Buchanan, G. O.; Regentin, R.; Hu, Z.; Hutchinson, C. R.; McDaniel, R. Chem. Biol. 2004, 11, 1625-1633.
16. Shimp, H. L.; Micalizio, G. C. Org. Lett. 2005, 7, 5111-5114.
17. Perez, L. J.; Shimp, H. L.; Micalizio, G. C. J. Org. Chem. 2009, 74, 7211-7219.
18. For examples in natural product synthesis, see: (c) Reichard, H. A.; Rieger, J. C.; Micalizio, G. C. Angew. Chem., Int. Ed. 2008, 47, 7837-7840.
19. Shimp, H. L.; Micalizio, G. C. Tetrahedron 2009, 65, 5908-5915.
20. Wu, J.; Panek, J. S. Angew. Chem., Int. Ed. 2010, 49, 6165-6168.
21. The C8-C15 subunit was available using our previously described synthesis strategy, while the other subunits were prepared by well-established methods. See the Supporting Information for details.
22. Hoffmann, R. W. Angew. Chem., Int. Ed. 1992, 31, 1124-1134.
23. Barton, D. H. R.; McCombie, S. W. J. Chem. Soc., Perkin Trans. 1 1975, 1574-1585.
24. Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. Chem. Rev. 1994, 94, 2483-2547.
25. Kocovsky, P. Tetrahedron Lett. 1986, 27, 5521.
26. Carter, K. D.; Panek, J. S. Org. Lett. 2004, 6, 55-57.
27. Investigation of alternative reagents and reaction conditions to address the low yield encountered in this step is currently underway. The installation of this carbamate in total syntheses has been accomplished with NaOCN, TFA (see ref 2 for an early example).
28. 3 during the collapse of the tetrahedral intermediate during final methanolysis. We suspect that this anomalous reaction pathway will be supressed by conducting the hydrolysis under aqueous conditions. This was not pursued in the current study but will be addressed in future work.
29. Kim, J.; Felts, S.; Llauger, L.; He, H.; Huezo, H.; Rosen, N.; Chiosis, G. J. Biomol. Screen. 2004, 9, 375-381.
30. Ge, J., Mormant, E.; Porter, J. R.; Ali, J. A.; Dembski, M. S.; Gao, Y.; Georges, A. T.; Grenier, L.; Pak, R. H.; Patterson, J.; Sydor, J. R.; Tibbitts, T. T.; Tong, J. T.; Adams, J.; Palombella, V. J. J. Med. Chem. 2006, 49, 4606-4615.
31. Gopalsamy, A.; Shi, M.; Golas, J.; Vogan, E.; Jacob, J.; Johnson, M.; Lee, F.; Nilakantan, R.; Petersen, R.; Svenson, K.; Chopra, R.; Tam, M. S.; Wen, Y.; Ellingboe, J.; Arndt, K.; Boschelli, F. J. Med. Chem. 2008, 51, 373-375.